Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-CD300A Recombinant Antibody (P192) (CBMAB-C0761-CN)


See all CD300A antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human
Clone
P192
Antibody Isotype
IgG2a
Application
FC

Basic Information

Immunogen
Polyclonal population of NK cells.
Host Species
Mouse
Specificity
Human
Antibody Isotype
IgG2a
Clonality
Monoclonal Antibody
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
FC1:25-1:200

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS
Preservative
0.09% sodium azide
Concentration
1 mg/ml

Target

Full Name
CD300a Molecule
Introduction
CD300A (CD300a Molecule) is a Protein Coding gene. Diseases associated with CD300A include Kabuki Syndrome 1. Among its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. Gene Ontology (GO) annotations related to this gene include phosphatidylserine binding and signaling receptor activity. An important paralog of this gene is CD300C.
Entrez Gene ID
11314
UniProt ID
Q9UGN4
Function
Inhibitory receptor which may contribute to the down-regulation of cytolytic activity in natural killer (NK) cells, and to the down-regulation of mast cell degranulation (PubMed:10746781, PubMed:16339535, PubMed:9701027).
Negatively regulates the Toll-like receptor (TLR) signaling mediated by MYD88 but not TRIF through activation of PTPN6 (PubMed:22043923).
Biological Process
Cell adhesion Source: UniProtKB-KW
Negative regulation of activation of Janus kinase activity Source: UniProtKB
Negative regulation of B cell proliferation Source: UniProtKB
Negative regulation of B cell receptor signaling pathway Source: UniProtKB
Negative regulation of eosinophil activation Source: UniProtKB
Negative regulation of eosinophil migration Source: UniProtKB
Negative regulation of fibroblast proliferation Source: UniProtKB
Negative regulation of MAP kinase activity Source: UniProtKB
Negative regulation of mast cell activation involved in immune response Source: UniProtKB
Negative regulation of mast cell degranulation Source: UniProtKB
Negative regulation of MyD88-dependent toll-like receptor signaling pathway Source: UniProtKB
Negative regulation of neutrophil activation Source: UniProtKB
Negative regulation of NK T cell activation Source: UniProtKB
Negative regulation of phagocytosis, engulfment Source: UniProtKB
Neutrophil degranulation Source: Reactome
Positive regulation of phosphoprotein phosphatase activity Source: UniProtKB
Regulation of immune response Source: Reactome
Regulation of T cell receptor signaling pathway Source: UniProtKB
Cellular Location
Cell membrane
Topology
Extracellular: 18-180
Helical: 181-201
Cytoplasmic: 202-299
PTM
Phosphorylated on tyrosine.
N-glycosylated.
More Infomation

Nakahashi-Oda, C., Fujiyama, S., Nakazawa, Y., Kanemaru, K., Wang, Y., Lyu, W., ... & Shibuya, A. (2021). CD300a blockade enhances efferocytosis by infiltrating myeloid cells and ameliorates neuronal deficit after ischemic stroke. Science Immunology, 6(64), eabe7915.

Cao, Y., Ao, T., Wang, X., Wei, W., Fan, J., & Tian, X. (2021). CD300a and CD300f molecules regulate the function of leukocytes. International Immunopharmacology, 93, 107373.

Formentini, M., Navas, A., Hassouneh, F., Lopez-Sejas, N., Alonso, C., Tarazona, R., ... & Pera, A. (2021). Impact of CMV and age on T cell subsets defined by CD161, CD300a, and/or CD57 expression in healthy Andalusians. The Journals of Gerontology: Series A.

Barroso, R., Bicknell, R., Rainger, G. E., Watson, S. P., & Sun, Y. (2021). AVEXIS technology identifies novel platelet-leukocyte binding partners including CD148-CD300a. Blood Advances, 5(23), 5016-5019.

Vitallé, J., Terrén, I., Orrantia, A., Pérez-Garay, R., Vidal, F., Iribarren, J. A., ... & Borrego, F. (2019). CD300a inhibits CD16-mediated NK cell effector functions in HIV-1-infected patients. Cellular & molecular immunology, 16(12), 940-942.

Sun, X., Huang, S., Wang, X., Zhang, X., & Wang, X. (2018). CD300A promotes tumor progression by PECAM1, ADCY7 and AKT pathway in acute myeloid leukemia. Oncotarget, 9(44), 27574.

Vitallé, J., Terrén, I., Gamboa-Urquijo, L., Orrantia, A., Tarancón-Díez, L., Genebat, M., ... & Borrego, F. (2018). Altered expression of CD300a inhibitory receptor on CD4+ T cells from human immunodeficiency virus-1-infected patients: association with disease progression markers. Frontiers in immunology, 9, 1709.

Tang, Z., Cai, H., Wang, R., & Cui, Y. (2018). Overexpression of CD300A inhibits progression of NSCLC through downregulating Wnt/β-catenin pathway. OncoTargets and therapy, 11, 8875.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CD300A Recombinant Antibody (P192)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry